A recent National Cancer Institute study shows that a new targeted therapy can help prolong the time cancer patients are in remission. Called the ViPOR regimen, the non-chemotherapy treatment shrinks tumors of those who suffer from B-cell lymphoma. Dr. Christopher Melani, associate research physician with the Lymphoid Malignancies Branch in the Center for Cancer Research at NCI, highlights the importance of combining five therapies and administering them during a fixed cycle to maximize drug synergy and make tumors disappear. He also shares details about the second phase of the study that is expected to take place later this year as well as how precision medicine could potentially lead to a cure for all types of cancer.